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Summary Secondary hyperparathyroidism is a com-
plex disorder requiring an individualized multicom-
ponent treatment approach. This study was con-
ducted to identify treatment combinations used in
clinical practice in Austria and Switzerland and the
potential to control this disorder. A total of 333 adult
hemodialysis and peritoneal dialysis patients were an-
alyzed. All patients received conventional care prior
to initiation of a cinacalcet-based regimen. During
the study, treatment components, e.g. cinacalcet,
active vitamin D analogues and phosphate binders,
were adapted to individual patient requirements and
treatment dynamics were documented. Overall, the
mean intact parathyroid hormone (iPTH) increased
from 64.2 pmol/l to 79.6 pmol/l under conventional
therapy and decreased after cinacalcet initiation to
44.0 pmol/l after 12 months (mean decrease between
baseline and 12 months –45%). Calcium remained
All authors meet the guidelines for authorship developed by
the International Committee of Medical Journal Editors
(ICMJE: http://www.icmje.org/) and agree to be accountable
for all aspects of the work.
Electronic supplementary material The online version of
this article (doi: 10.1007/s00508-016-1153-z) contains
supplementary material, which is available to authorized
users.
Dr. W. Pronai ()
Department of Internal Medicine, Dialysis Unit, Hospital of
the Brothers of Saint John of God, Johannes von Gott
Platz 1, 7001 Eisenstadt, Austria
Wolfgang.Pronai@bbeisen.at
A. R. Rosenkranz
Department of Internal Medicine, Clinical Division of
Nephrology, Medical University of Graz, Graz, Austria
within the normal range throughout the study and
phosphorus ranged around the upper limit of normal.
The Kidney Disease: Improving Global Outcomes
(KDIGO) target achievement for iPTH increased from
44.5% of patients at baseline to 65.7% at 12 months,
corrected calcium from 58.9% to 51.9% and phospho-
rus from 18.4% to 24.4%. On average, approximately
30% of patients adapted their regimen from one ob-
servation period to the next. The reasons for changing
a given regimen were to attain or maintain any of the
bone mineral markers within recommended targets
and to avoid developments to extreme values. Some
regional differences in practice patterns were identi-
fied. No new safety signals emerged. In conclusion,
cinacalcet appears to be a necessary treatment com-
ponent to achieve recommended targets. The detailed
composition of the treatment mix should be adapted
to patient requirements and reassessed on a regular
basis.
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Introduction
Secondary hyperparathyroidism (SHPT) is a severe
and progressive disorder frequently observed in pa-
tients from an early stage of chronic kidney disease
(CKD) onwards. At the time this study was planned
and initiated, in the years 2009/2010, the princi-
ples of therapy of SHPT were profoundly questioned
and changed. A new theory of the pathogenesis of
SHPT placed more emphasis on the control of serum
phosphorus levels [1]. This newer theory views the
CKD-induced impaired activation of vitamin D not
as the cause of SHPT but as an adaptive reaction to
processes occurring much earlier in the cascade of
events. According to this theory phosphorus retention
in the failing kidney leads to increases in circulating
fibroblast growth factor 23 (FGF-23) levels. Together
with the Klotho protein FGF-23 tries to restore effec-
tive renal phosphorus clearance. In addition, FGF-
23 blocks the production of active vitamin D. Only
in the very late stages of CKD, when no sufficient
renal function remains and phosphorus clearance
can no longer be supported by intrinsic mechanisms,
the PTH-calcium-vitamin D axis as described in the
“trade-off” comes into play [2]. Following this rea-
soning, SHPT treatment should primarily be based on
phosphorus restriction in combination with physio-
logic doses of active vitamin D analogues. In patients
where phosphate binders and physiologic vitamin D
doses alone are insufficient to control parathyroid
hormone (PTH), calcimimetics should be consid-
ered as first-line therapy to control serum PTH [1].
On the other hand, the Kidney Disease: Improving
Global Outcomes (KDIGO) Chronic Kidney Disease
– Mineral and Bone Disorder (CKD-MBD) guidelines
issued in 2009 [3] were less stringent with respect
to PTH target levels than the previously used Na-
tional Kidney Foundation Kidney Disease Outcomes
Quality Initiative (NKF-KDOQI™) guidelines [4]. The
2003 NKF-KDOQI™ clinical practice guidelines for
bone mineral metabolism and disease in CKD de-
fined stringent target ranges for the key parameters of
bone mineral metabolism (iPTH: 16.5–33.0 pmol/l;
serum phosphorus: 1.1–1.78mmol/l; serum cal-
cium: 2.1–2.37mmol/l; corrected calcium-phospho-
rus product <4.4mmol²/l²) [4]. In 2009, the KDIGO
clinical practice guidelines for the diagnosis, evalua-
tion, prevention and treatment of CKD-MBD changed
their focus towards defining ranges of extreme risk
that should be avoided [3]. For intact PTH (iPTH), the
recommended safe range was defined as 2–9 times
the upper limit of normal (ULN) of the assay used;
calcium is recommended to be maintained in the
normal range and elevated phosphorus should be
lowered toward the normal range. These recommen-
dations allow some individualization of treatment
much welcomed by the medical community.
At the time this study was planned a survey evaluat-
ing the quality of CKD-MBD treatment in Austria (Aus-
trian Dialysis and Transplant Registry; “QUASI” 2008,
www.nephro.at), revealed that approximately 30% of
Austrian patients received cinacalcet as a monother-
apy, without concomitant administration of active vi-
tamin D compounds. From the survey, however, it was
not clear, whether cinacalcet was used as a monother-
apy already at cinacalcet initiation or if active vita-
min D was initially co-administered and discontinued
later. One aim of this study therefore was to determine
the proportion of patients where cinacalcet was initi-
ated as a monotherapy or in combination with active
vitamin D. Another aim of this study was to identify
treatment combinations used in clinical practice and
their potential to control CKD-MBD.
Methods
Study design
The TReatment prActice for maNagement of SHPT
with cInacalcet and viTamin D (TRANSIT) study was
a single-arm, partly retrospective, partly prospective
observational study conducted in Austria and Switzer-
land. The observation period was 18 months: data
were collected 6 months prior to cinacalcet initiation
(month -6) or from start of dialysis onwards in pa-
tients with less than 6 months of dialysis vintage un-
til 12 months after cinacalcet initiation (month 12).
There was no control group. The study design al-
lowed retrospective, intraindividual, longitudinal con-
trol. This study was non-interventional, i. e. no study-
related changes to routine clinical treatment, changes
in therapy or co-medication, diagnostic work-up or
monitoring of participating patients were foreseen in
the study protocol, nor were additional hospital vis-
its required for the sole purpose of meeting study re-
quirements. Patients were only included if cinacal-
cet treatment was initiated prior to study inclusion to
avoid initiation of the drug for the purpose of partic-
ipation in this study. Cinacalcet treatment was con-
ducted according to the approved indications and the
judgment of the treating physician.
Eligibility
Hemodialysis and peritoneal dialysis patients ≥18 years
of age and indicated for treatment with cinacalcet ac-
cording to the label were included, if they had been
initiated on cinacalcet for no longer than 3 months
prior to inclusion in this study. Patients contraindi-
cated for treatment with cinacalcet as per label, pa-
tients participating in a clinical trial expected to
confound the endpoints of this study or patients with
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planned kidney transplantation within the observa-
tion period of this study were excluded.
Participating centers and sample size estimation
The total planned patient number was approximately
330, based on experience from previous observational
studies in the participating countries. The similarly
designed Austrian Evaluation of the Clinical Use of
Mimpara® in Hemodialysis and Peritoneal Dialysis Pa-
tients, an Observational Study (ECHO) enrolled 320
patients [5]. Dialysis centers were selected on the ba-
sis of relevant experience and an estimated recruit-
ment capacity of a minimum of five patients per cen-
ter. Representativeness of the totality of selected cen-
ters was defined by criteria, such as geographical re-
gion or type of center (e.g. urban, rural, academic and
non-academic).
Data collection
Data of eligible patients were collected from their
charts. Centers were asked to include all patients
newly initiated on cinacalcet within 3 months prior
to study start until the end of the enrollment period
or until the maximum number of 20 patients allowed
per center was reached. Eligible patients were in-
cluded in the study sequentially by date of cinacalcet
initiation. Patients were informed about the collec-
tion of the data for the purpose of this study and
were required to provide written informed consent.
For Austria, ethics committee approval was obtained
centrally from the institutional review board of the
Medical University of Graz, Austria. For Switzerland
no ethics committee approval was legally required at
the time of study conduct.
For the purpose of documentation, electronic or
paper case report forms (CRF) were completed by the
treating physician. Internal integrity and logic of data
were assured by checking the returned CRF for com-
pleteness, plausibility and obvious discrepancies. An
additional quality check encompassing 30% of data
in 10% of patients was conducted on site under strict
maintenance of data privacy by the means of indi-
rect methods (interview) to ensure consistency with
source documents. Only the treating physician had
direct access to patient files.
Study parameters
The primary study parameter was the proportion
(%) of end-stage renal disease patients with CKD-
MBD, who were initiated on a regimen of cinacal-
cet monotherapy without concomitant administra-
tion of active vitamin D compounds. Secondary
study parameters were mineral metabolite trajecto-
ries, NKF-KDOQI™ and KDIGO target achievement,
usage patterns of cinacalcet and relevant concomi-
tant medications (e.g. active vitamin D compounds
and phosphate binders), patient characteristics and
demographics and adverse event (AE) reports.
Since the KDIGO guidelines do not provide exact
target ranges, we used the ranges provided by the Aus-
trian Dialysis and Transplant Registry, who have stan-
dardized normal ranges over all assays used for the pa-
rameters of interest in Austria and set recommended
target ranges for iPTH (12.72–63.6 pmol/l), phos-
phorus (1.13–1.48mmol/l) and calcium (corrected
2.1–2.4mmol/l) [3, 6]. For NKF-KDOQI™ the pub-
lished target ranges were used (iPTH 16.5–33.0 pmol/l,
phosphorus 1.13–1.78mmol/l, corrected calcium
2.1–2.37mmol/l, and corrected calcium-phosphorus
product <4.44mmol²/l²) [4].
Treatment assignment
Classification of patients with respect to treatment
regimen type was based on their medication use at
each timepoint of interest. These regimen types com-
prised cinacalcet monotherapy, cinacalcet plus low
dose vitamin D (defined as a maximum dose of 2 μg
paricalcitol = 1 μg doxercalciferol = 1 μg alfacalcidol =
0.5 μg calcitriol administered intravenously with each
dialysis session, i. e. three times weekly, or a daily oral
dose of 1 μg paricalcitol = 0.5 μg alfacalcidol = 0.25 μg
calcitriol), cinacalcet plus high dose vitamin D (doses
higher than the ones defined as low dose vitamin D),
vitamin D monotherapy or no SHPT therapy. All pa-
tients in all groups were allowed to receive concomi-
tant phosphate binders. Patient flow charts were pre-
pared to illustrate the dynamics of CKD-MBD treat-
ment over time.
Statistical analysis
Patients were analyzed overall and by different treat-
ment regimen types. No formal hypothesis was tested.
The full analysis set (FAS) comprised all enrolled pa-
tients who were initiated on cinacalcet and who re-
ceived at least one dose of cinacalcet. Categorical vari-
ables are summarized as the percentage of patients
in each category. Continuous variables are presented
as means, standard deviations (SD), medians, mini-
mum andmaximum values and 95% confidence inter-
vals (CI) of means for the overall group are presented.
Only available entries were analysed and no last ob-
servation carried forward (LOCF) was conducted. In
the electronic case report form (eCRF) the following
conversion factors for conventional to SI units were
programmed: albumin g/d × 10 = g/l, Ca (total, ion-
ized) mg/dl × 0.25 = mmol/l, Ca × P mg2/dl2 × 0.08 =
mmol2/l2, iPTH pg/ml × 0.1053 = pmol/l and P mg/dl ×
0.323 = mmol/l.
For statistical analysis SPSS software, V.17 (IBM, Ar-
monk, NY) was used.
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Table 1 Patient demographicsandcharacteristics
Parameter Overall Austria Switzerland
Gender, n (%)
N 332 165 167
Male 204 (61.4) 103 (62.4) 101 (60.5)
Female 128 (38.6) 62 (37.6) 66 (39.5)
Ethnicity, n (%)
N 333 165 168
Caucasian 310 (93.1) 161 (97.6) 149 (88.7)
Black/African
American
13 (3.9) 1 (0.6) 12 (7.1)
Asian 8 (2.4) 3 (1.8) 5 (3.0)
Hispanic/Latino 2 (0.6) 0 2 (1.2)
Age, years
N 333 165 168
Mean (SD) 60.8 (14.4) 59.4 (14.9) 62.1 (13.7)
Median (min,
max)
62.0 (22, 89) 61.0 (22, 88) 64.0 (23, 89)
Weight, kg
N 331 165 166
Mean (SD) 78.3 (17.6) 81.3 (16.9) 75.4 (17.8)
Median (min,
max)
77.6 (36, 142) 80.0 (47, 139) 74.0 (36, 142)
Height, cm
N 321 165 156









Primary etiology of CKD, n (%)
N 333 165 168
Diabetes mellitus 98 (29.4.5) 57 (34.5) 41 (24.4)
Vascular
nephropathy
96 (28.8) 44 (26.7) 52 (31.0)
Glomerulonephritis 38 (11.4) 16 (9.7) 22 (13.1)
Polycystic
nephropathy
33 (9.9) 10 (6.1) 23 (13.7)
Interstitial
nephropathy
9 (2.7) 3 (1.8) 6 (3.6)
Other 83 (24.9) 48 (29.1) 35 (20.8)
Dialysis method, n (%)
N 333 165 168
Hemodialysis 320 (96.1) 163 (98.8) 157 (93.5)
Peritoneal dialy-
sis
13 (3.9) 2 (1.2) 11 (6.5)
iPTH at baseline, pmol/l
N 301 149 152









Calcium (corrected) at baseline, mmol/l
N 241 116 125










Parameter Overall Austria Switzerland
Phosphorous at baseline, mmol/l
N 321 158 163









PTH trigger to initiate cinacalcet, n (%)
N 323 165 158
iPTH > 33 pmol/l 150 (46.4) 87 (52.7) 63 (39.9)
iPTH > 9x ULN 40 (12.4) 15 (9.1) 25 (15.8)
Increasing iPTH
trend




31 (9.6) 4 (2.4) 27 (17.1)
CKD chronic kidney disease, N number of patients with available data,
SD standard deviation, ULN upper limit of normal of the assay used,
PTH parathyroid hormone, iPTH intact parathyroid hormone
Percentages are based on the number of patients with valid entries
Results
Study population
Between February 2010 and December 2013 data from
a total of 335 patients were collected. A total of 333
patients (Austria n = 165; Switzerland n = 168) were
analyzed and 2 patients were excluded from the anal-
ysis: 1 patient did not receive cinacalcet and 1patient
was <18 years of age. At month 12, data were available
from 241 patients (73.4%). Patient status at the end of
documentation was available from 333 patients: 238
(71.5%) had full documentation of 12 months of ob-
servation period and completed end of documenta-
tion status. Of the patients 66 (19.8%) had incomplete
documentation and provided a reason for discontin-
uation of which 27 (8.1%) died, 18 (5.4%) received a
transplant, 6 (1.8%) moved, 15 (4.5%) had other rea-
sons and 29 patients (8.7%) did not provide any status.
Patient demographics are shown in Table 1. Over-
all, almost all patients received hemodialysis (96.1%),
61.4% of patients were male and 93.1% were of Cau-
casian origin. The mean (SD) age was 60.8 (14.4) years
and the two most prevalent etiologies of CKD were
diabetes mellitus (29.4%) and vascular nephropathy
(28.8%).
CKD-MBD treatment patterns
At cinacalcet initiation (i.e. baseline), 31.2% of pa-
tients (n = 104) started cinacalcet without concomi-
tant vitamin D therapy (primary outcome measure).
Table 1 lists the iPTH triggers to initiate cinacalcet at
baseline. The two most important triggers were an
iPTH > 33 pmol/l (46.4%, n = 150) and an increasing
iPTH trend (31.6%, n = 102). The two most impor-
tant primary reasons to start cinacalcet were to reduce
PTH in patients with hyperphosphatemia (56.3%, n =
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174) or to reduce PTH in patients with normophos-
phatemia and normocalcemia (21.7%, n = 67; Figure
S2). In addition to cinacalcet monotherapy, 37.8% of
patients (n = 126) received cinacalcet in combination
with high dose vitamin D and 28.5% (n = 95) received
cinacalcet plus low dose vitamin D. Over time, the
proportion of patients assigned to these groups re-
mained relatively stable, with approximately 20% of
patients remaining on cinacalcet monotherapy, ap-
proximately 30% remained on cinacalcet plus high
dose vitamin D, and approximately 20% remained on
cinacalcet plus low dose vitamin D throughout the 12-
month study duration. On an individual level, how-
ever, regimens were adjusted to meet patients’ needs
(Fig. 1, Table S1). Starting with month 3, patients
interrupting or permanently discontinuing cinacalcet
emerge. The most important primary reasons to dis-
continue or interrupt cinacalcet were PTH suppres-
sion (39.4%, n = 39) and other reasons (37.4%, n =
37). Of the patients 12 (12.1%) stopped or interrupted
cinacalcet because they had reached the target range
for iPTH (Figure S2.B). At month 12, 198 (82.6%) out of
241 patients with available values received cinacalcet.
Patients stopping cinacalcet continued on two pos-
sible regimens: vitamin D monotherapy or no SHPT
therapy, both of which included optional phosphate
binders.
The median daily cinacalcet dose was 30.0mg at all
timepoints overall and in all groups that had cinacal-
cet as their treatment backbone. Themean daily doses
increased from 30.7mg (95% CI ± 0.83mg) overall at
baseline to 45.4mg (95% CI ± 3.37mg) at month 12
(Table S2). The highest mean dose at month 12 was
observed in the cinacalcet monotherapy group with
50.9mg/week (baseline: 30.4mg/week), the lowest in
the cinacalcet plus low dose vitamin D group with
39.8mg/day (baseline: 30.0mg/day). In patients re-
ceiving active vitamin D analogues the majority of
patients received oral calcitriol (ranging over time be-
tween 60% and 65% of those patients with valid vita-
min D doses), followed by i. v. alfacalcidol (11–15%),
i. v. paricalcitol (9–13%), and oral alfacalcidol (5–9%).
Themedian weekly vitamin D dose was 6.0 µg i. v. par-
icalcitol equivalents at all timepoints overall and in the
cinacalcet plus low dose vitamin D group, 14.0 µg in
the cinacalcet plus high dose vitamin D group and be-
tween 12.0 and 14.0 µg in the vitamin D monotherapy
group. The mean weekly doses ranged around 11 µg
overall throughout the study, with approximately 5 µg
in the cinacalcet plus low dose vitamin D group and
14 to 15 µg in the cinacalcet plus high dose vitamin D
group.
All treatment groups optionally included phosphate
binders (Table S2). Overall, the proportion of pa-
tients receiving phosphate binders remained stable
between 60% and 66% of patients, with approximately
20% of patients receiving more than one phosphate
binder. The proportion of patients receiving calcium-
based phosphate binders varied over time between 47
and 51%; the proportion of patients receiving non-
calcium-based phosphate binders had an increasing
trend from 42% at month –3 to 53% at month 12. This
category includes a relatively constant group of pa-
tients (12 to 16%) receiving aluminium-based phos-
phate binders (Table S2).
Mineral markers over time
Overall, mean iPTH increased from 64.2 pmol/l (95%
CI ± 5.90) 3 months before baseline to 79.6 pmol/l
(95% CI ± 5.64) at baseline and decreased thereafter to
44.0 pmol/l (95% CI ± 5.20) at month 12. Among the
different study groups, the mean baseline iPTH value
in patients with cinacalcet monotherapy or cinacal-
cet plus high dose vitamin D was higher than in pa-
tients with cinacalcet plus low dose vitamin D pa-
tients. At study end, iPTH values were within target
in all groups (Fig. 2). Overall, the mean percentage
decrease in iPTH between baseline and month 12 was
–45%; the largest reduction was found in patients re-
ceiving cinacalcet monotherapy (–45%; Table 2). At
month 3, the first patients interrupted cinacalcet ther-
apy, receiving either vitamin D monotherapy or no
SHPT therapy at all. In the vitamin D monother-
apy group, mean iPTH decreased from 70.6mmol/l
(range 6.0 to 241.9) at month 3 to 46.3mmol/L (range
6.6 to 220.6) at month 12. In the no SHPT therapy
group, patients had very low PTH values at month 3
(mean 29.6mmol/l; range 4.2 to 100.1), which rose to
57.2mmol/l (range 1.6 to 209.5) at month 12 (Fig. 2).
Mean corrected serum calcium remained within
target over time with a trend towards higher calcium
in patients receiving vitamin D monotherapy or no
SHPT therapy compared to the other groups (Fig. 3).
Mean serum phosphorus ranged around the upper
limit of the recommended target range during the en-
tire study period (Fig. 4).
Note: since the KDIGO guidelines do not provide
exact target ranges, reference ranges provided by the
Austrian Dialysis and Transplant Registry were used
(12.72–63.6 pmol/l), phosphorus (1.13–1.48mmol/l),
and calcium (corrected; 2.1–2.4mmol/l) [3, 6]. For
NKF-KDOQI™ the published target ranges were
used (iPTH: 16.5–33.0 pmol/l, phosphorus: 1.13–1.78
mmol/l, corrected calcium: 2.1–2.37mmol/l, and cor-
rected calcium-phosphorus product: <4.44mmol²/l²)
[4]. Cinacalcet mono, subgroup of patients receiv-
ing cinacalcet monotherapy at the specific point in
time; cinacalcet + high vit D, subgroup of patients
receiving cinacalcet plus high dose active vitamin D
compounds at the specific point in time; cinacalcet +
low vit D, subgroup of patients receiving cinacalcet
plus low dose active vitamin D compounds at the
specific point in time (low dose active vitamin D was
defined as a maximum of 2 µg intravenous paricalcitol
three times weekly or equivalent).
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Fig. 1 Group dynamics of SHPT therapies over time. a Base-
line to month 6. bMonth 6 tomonth 12. Cinacalcet mono, sub-
group of patients receiving cinacalcet monotherapy at the spe-
cificpoint intime;cinacalcet+highvitD,subgroupofpatientsre-
ceivingcinacalcetplushighdoseactivevitaminDcompoundsat
the specificpoint in time; cinacalcet + lowvitD, subgroupof pa-
tients receiving cinacalcet plus low dose active vitamin D com-
pounds at the specific point in time (low dose active vitamin D
wasdefinedasamaximumof2 μg intravenousparicalcitol three
timesweeklyor equivalent)

















KDOQI range: 13.5–33.0 pmol/l
KDIGO range: 12.72–63.6 pmol/l
Mean iPTH, pmol/L
overall 64.2 74.7 79.6 56.6 50.5 45.6 44.0
cinacalcet mono 86.9 53.9 52.8 49.9 47.8
cinacalcet + low vit D 70.0 52.1 41.5 40.5 36.8
cinacalcet + high vit D 81.2 60.5 56.9 45.0 44.0
vit D mono 70.6 49.1 50.7 46.3
no SHPT therapy 29.6 27.8 45.9 57.2
Patient numbers
overall 220 152 301 294 280 253 213
cinacalcet mono 90 80 70 59 49
cinacalcet + low vit D 89 77 68 58 51
cinacalcet + high vit D 117 110 108 93 75
vit D mono 12 20 20 21
no SHPT therapy 7 8 17 13
Fig. 2 Bonemineralmarkersover time.Median iPTHover time (pmol/l)














Overall –45 (n = 301) –13 (n = 280) –46 (n = 149) –9 (n = 146) –43 (n = 152) –16 (n = 134)
Cinacalcet mono –45 (n = 90) –9 (n = 70) –44 (n = 35) 9 (n = 31) –45 (n = 55) –19 (n = 39)
Cinacalcet + low vit D –47 (n = 89) –11 (n = 68) –53 (n = 39) –21 (n = 35) –42 (n = 50) 2 (n = 33)
Cinacalcet + high vit D –46 (n = 117) –23 (n = 108) –42 (n = 74) –14 (n = 60) –52 (n = 43) –31 (n = 48)
Vit D monoa – –6 (n = 21) – 19 (n = 12) – –22 (n = 9)
No SHPT therapya – 106 (n = 13) – 63 (n = 6) – 90 (n = 7)
aPatients receiving vitamin D monotherapy or no SHPT therapy first appear at month 3
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Mean Ca (corr), mmol/L
overall 2.29 2.27 2.27 2.17 2.18 2.19 2.21
cinacalcet mono 2.25 2.17 2.21 2.17 2.23
cinacalcet + low vit D 2.29 2.16 2.10 2.12 2.14
cinacalcet + high vit D 2.27 2.17 2.20 2.22 2.23
vit D mono 2.26 2.34 2.28 2.32
no SHPT therapy 2.34 2.35 2.30 2.25
Patient numbers
overall 207 169 241 255 246 213 185
cinacalcet mono 75 64 60 44 32
cinacalcet + low vit D 69 67 60 53 46
cinacalcet + high vit D 91 98 92 80 72
vit D mono 11 17 17 20















KDOQI range: 2.10–2.37 mmol/L
Fig. 3 Mediancalcium (corrected) over time (mmol/l)
Target achievement
The NKF-KDOQI™ as well as KDIGO target achieve-
ments were assessed, since the study started only
a few months after the publication of the KDIGO
guidelines and a certain degree of overlap of ad-
herence to one of these guidelines was expected in
clinical practice. Overall, 44.5% of patients (n = 134 of
301) reached KDIGO targets and 4.3% (n = 13 of 301)
reached NKF-KDOQI™ targets for iPTH at baseline,
while 65.7% of patients (n = 140 of 213) and 30.0% of
patients (n = 64 of 213) reached the respective targets
at month 12. Target achievement for corrected cal-
cium remained stable, with 58.9% (n = 142 of 241) and
52.7% (n = 127 of 241) at baseline versus 51.9% (n =
96 of 185) and 49.7% (n = 92 of 185) at month 12, re-
spectively. Phosphorus targets were reached in 18.4%
(n = 59 of 321) and 45.2% (n = 145 of 321) at baseline
versus 24.4% (n = 57 of 234) and 50.4% (n = 118 of
234) at month 12, respectively. Results for the overall
group and the subgroups are depicted in Fig. 5 and
Figure S1.
Safety
Safety was not formally evaluated. Within the frame-
work of their pharmacovigilance responsibilities, in-
vestigators reported a total of 11 drug-related adverse
events in 8 patients (2.4%), 3 of which were considered
as serious (dyspepsia, n = 2; seroma, n = 1).
Discussion
The TRANSIT study evaluated the different treatment
combinations used in clinical practice to treat CKD-
MBD. All patients were initiated on a cinacalcet-
Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment. . . K
original article
Mean P, mmol/L
overall 1.81 1.86 1.87 1.77 1.73 1.69 1.71
cinacalcet mono 1.90 1.84 1.78 1.74 1.71
cinacalcet + low vit D 1.90 1.75 1.69 1.67 1.75
cinacalcet + high vit D 1.84 1.75 1.75 1.68 1.72
vit D mono 1.94 1.60 1.65 1.66
no SHPT therapy 1.79 1.80 1.70 1.54
Patient numbers
overall 261 267 321 312 302 275 234
cinacalcet mono 96 84 76 65 49
cinacalcet + low vit D 95 82 73 64 56
cinacalcet + high vit D 122 118 112 97 82
vit D mono 13 21 23 26

















KDOQI range: 1.13 to 1.78 mmol/L
Fig. 4 Medianphosphorusover time (mmol/l)
based regimen. Treatment components, cinacalcet,
active vitamin D analogues and phosphate binders,
were subsequently adapted to individual patient re-
quirements. We grouped patients according to their
individual treatment at each 3-month interval and de-
scribed the evolution of treatment patterns and bone
mineral markers over time, thus capturing treatment
dynamics. An analysis of group dynamics showed that
although the overall proportion of patients within
each type of treatment remained relatively stable,
a substantial proportion of patients switched between
treatments. To our knowledge, this is the first report
tracing the dynamics of individualized treatment for
CKD-MBD in clinical practice over time. On average,
approximately 30% of patients changed their regimen
from one 3-month period to any of the other possible
treatment types. The reasons for changing a given
regimen were to bring to or maintain any of the bone
mineral markers within recommended targets and to
avoid developments to the extreme (Figure S2).
The present analysis observed daily clinical prac-
tice in the participating countries without any study-
specific intervention and therefore provides valuable
insights into local treatment patterns. Although the
trends are similar overall and in the countries, some
marked differences were observed. For instance,
corrected calcium tended to be higher in Switzer-
land than Austria, whereas phosphorus tended to
be lower (Figure S3). In Switzerland, a substan-
tially larger proportion of patients (37.5%) received
cinacalcet monotherapy at baseline, without con-
comitant active vitamin D analogues, compared to
Austria (24.8%; Table 2). In Austria a larger propor-
tion of patients received aluminium-based phosphate
binders compared to Switzerland (Table S2). Both
NKF-KDOQI™ and KDIGO target achievement rates
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Proportion of patients achieving target














BL 44.5% 58.9% 18.4% 37.8% 61.3% 17.7% 51.7% 52.2% 20.0% 44.4% 61.5% 17.2%
M 12 65.7% 51.9% 24.4% 59.2% 37.5% 20.4% 66.7% 54.3% 32.1% 72.0% 54.2% 20.7% 52.4% 60.0% 26.9% 61.5% 54.5% 33.3%
Patient numbers, n/N
BL 134/301 142/241 59/321 34/90 46/75 17/96 46/89 36/69 19/95 52/117 56/91 21/122 - - - - - -

























overall cinacalcet mono cinacalcet + low vit D cinacalcet + high vit D vit D mono no SHPT therapy
Fig. 5 Target achievement at baseline and at month 12, over-
all and by subgroups. Proportion of patients (95% CI) reach-
ingKDIGOrecommendedtarget ranges,basedon“normal”val-
ues from the Austrian dialysis and transplantation registry [5]:
iPTH (12.72–63.6 pmol/l), phosphorus (1.13–1.48mmol/l), and
calcium (corrected; 2.1–2.4mmol/l) [3, 6]. n number of patients
in target, N number of patients with available values. Cinacal-
cetmono, subgroup of patients receiving cinacalcetmonother-
apyatthespecificpoint intime;cinacalcet+highvitD,subgroup
of patients receiving cinacalcet plus high dose active vitamin D
compounds at the specific point in time; cinacalcet + low vit D,
subgroup of patients receiving cinacalcet plus low dose active
vitamin D compounds at the specific point in time (lowdose ac-
tivevitaminDwasdefinedasamaximumof2 μgintravenouspar-
icalcitol three timesweeklyor equivalent)
again were similar in both countries (Figure S4).
There are many possible causes for these differences
in treatment practice, such as local guidelines and
treatment patterns, cost factors and reimbursement
rules, differences in diet and phosphorus intake, dif-
ferences in baseline characteristics or co-morbidities.
We have not conducted an analysis of covariates to
precisely determine associations between differences
in patient-related factors and subsequent evolution
of bone mineral marker levels or target achievement.
A similarly designed study conducted in several Euro-
pean countries, ECHO, also found marked differences
in treatment patterns, biomarker levels and target
achievement between countries and provides a dis-
cussion of possible reasons [5, 7].
Austria and Switzerland have different reimburse-
ment rules. In the SHPT indications, Austrian health
insurances restricted the reimbursement of cinacalcet
to dialysis patients with serum PTH above 33.0 pmol/l
in whom conventional therapy with phosphate binders
and vitamin D analogues the PTH target of 16.5 to
33.0 pmol/l demonstrably could not be reached or
maintained. Treatment with cinacalcet may only be
extended to a maximum of 6 months in responders
with a decrease in serum PTH of >30% after 12 weeks
of treatment. Restrictions in phosphate binder type
apply. In Switzerland cinacalcet is reimbursed in dial-
ysis patients with SHPT and a PTH above 33.0 pmol/l,
when prescribed by a nephrologist. The limitation to
second line therapy in Austria may explain the much
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smaller proportion of patients receiving cinacalcet
monotherapy at baseline. Also the differences in the
reasons for treatment adaptations (Figures S2) may
be justified in the regulatory background.
The baseline characteristics and demographics in
the present study were comparable to patients in the
Austrian Dialysis and Transplant Registry [6]. Un-
fortunately, a comparable registry does not exist in
Switzerland. According to the Austrian registry, the
majority of Austrian centers follow the KDIGO rec-
ommendations and they use these recommendations
as the basis for their quality assurance initiative. We
analyzed both achievement of targets recommended
by the NKF-KDOQI™ and KDIGO guidelines. Our
analysis showed that more patients (66%) achieved
the wider KDIGO target range (12.72 to 63.6 pmol/l)
for iPTH compared to the NKF-KDOQI™ recom-
mended range (13.5 to 33.0 pmol/l; 30%). Findings
were comparable between Austria and Switzerland by
either definition of target. The proportion of patients
achieving KDIGO target ranges for iPTH was similar
to the findings of the Austrian registry (69%; [6]).
The Austrian subanalysis of the ECHO study showed
that 36% of patients reached NKF-KDOQI™ targets
for iPTH, which is similar to our findings [5]. Across
Europe, ECHO found a large variability of 13.5% (UK/
Ireland) to 40% of patients (Czech Republic/Slovakia)
achieving the NKF-KDOQI™ target for iPTH [7].
Compared to NKF-KDOQI™ (1.13 to 1.78mmol/l),
KDIGO guidelines have a narrower target range for
phosphorus (1.13–1.48mmol/l, defined as the “nor-
mal” range of assays commonly used in Austria)
and fewer patients (24%) reached phosphorus tar-
gets as recommended by KDIGO than compared to
NKF-KDOQI™ (50%). Our findings compare posi-
tively to the ECHO study, where NKF-KDOQI™ target
achievement for phosphorus ranged between 26.2%
(CEE country cluster) and 59.4% (Italy). It is a com-
mon finding for Austria that phosphorus levels tend
to range around the upper limit of the target range. In
the registry, 24% of patients are within the phospho-
rus target range, with 66% being above. In Switzer-
land, however, phosphorus levels trended to be lower
compared to Austria and more Swiss than Austrian
patients achieved either target definition.
Approximately 50% of patients remained in the
NKF-KDOQI™ range for corrected calcium across the
entire study. Since the target range used to repre-
sent KDIGO recommendations of the “normal” range
(2.1 to 2.4mmol/l, not rounded, personal communi-
cation R. Kramar, president of the Austrian dialysis
and transplant registry, Klinikum Wels-Grieskirchen,
Austria) is slightly wider on the upper limit than
the NKF-KDOQI™ range (2.1–2.37mmol/l), more
patients reached KDIGO targets at baseline (58.9%)
compared to NKF-KDOQI™ (52.7%), with a slight de-
cline in target achievement over time (51.9%, KDIGO;
49.7%, NKF-KDOQI™). In the ECHO study, between
40.8% (UK/Ireland) and 59.3% (Nordic country clus-
ter) reached NKF-KDOQI™ targets for corrected cal-
cium. Slightly fewer patients reached calcium targets
in Switzerland compared to Austria. Calcium reduc-
tion is a known effect of cinacalcet.
This study has some special features. In the attempt
to capture the dynamics of SHPT treatment, at each
of the evaluated timepoints each patient was newly
assigned to the group that best reflected their treat-
ment type. This implies that the welfare of patients
receiving a particular treatment type, as a group, is
not followed longitudinally. The composition of the
groups and thus their patient characteristics is differ-
ent at each timepoint. This type of analysis provides
a very clear picture of everyday clinical practice and
suggests that minute adaptations in treatment com-
position may be partly responsible for treatment suc-
cess. It does, however, not allow conclusions on the
relative benefit of one particular treatment type over
the other to be deduced. This question can only be an-
swered in an interventional study where patients are
assigned to specific treatment types and maintained
over time.
In summary, in Austrian and Swiss clinical practice,
cinacalcet is commonly started in combination with
active vitamin D analogues. Overall, iPTH trended to
increase prior to cinacalcet initiation and decreased
afterwards by 43–58% compared to baseline and 66%
of patients achieved KDIGO targets for iPTH at study
end. Patients’ treatment combinations were con-
stantly adjusted to their needs at each timepoint to
optimize individual outcomes. IPTH increased prior
to cinacalcet initiation, despite treatment with con-
ventional therapies such as vitamin D analogues and
phosphate binders; phosphorus also showed a rising
trend. After initiation of cinacalcet iPTH and phos-
phorus decreased to levels within the recommended
target range. Treatment was highly dynamic and
tailored to individual needs.
Conclusion
The results of this study suggest that cinacalcet is
a useful treatment component to achieve recom-
mended targets. The details of the treatment mix are
subject to individual patient requirements and should
be re-assessed on a regular basis.
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